| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tamoxifen | 55 | 2024 | 963 | 5.620 |
Why?
|
| Antineoplastic Agents, Hormonal | 57 | 2024 | 1534 | 3.890 |
Why?
|
| Breast Neoplasms | 118 | 2025 | 21056 | 3.640 |
Why?
|
| Receptors, Estrogen | 41 | 2025 | 2242 | 2.930 |
Why?
|
| Receptors, Progesterone | 28 | 2025 | 1153 | 2.620 |
Why?
|
| Premenopause | 24 | 2024 | 1037 | 2.350 |
Why?
|
| Aromatase Inhibitors | 24 | 2024 | 518 | 2.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2024 | 11868 | 2.180 |
Why?
|
| Chemotherapy, Adjuvant | 61 | 2024 | 3537 | 1.980 |
Why?
|
| Androstadienes | 14 | 2024 | 347 | 1.970 |
Why?
|
| Ovary | 11 | 2019 | 956 | 1.860 |
Why?
|
| Carcinoma, Renal Cell | 22 | 2024 | 3181 | 1.750 |
Why?
|
| Nitriles | 21 | 2024 | 982 | 1.670 |
Why?
|
| Kidney Neoplasms | 22 | 2024 | 4274 | 1.580 |
Why?
|
| Receptor, erbB-2 | 29 | 2025 | 2593 | 1.560 |
Why?
|
| Inflammatory Breast Neoplasms | 10 | 2024 | 150 | 1.500 |
Why?
|
| Prostatic Neoplasms | 67 | 2024 | 11083 | 1.470 |
Why?
|
| Triazoles | 17 | 2020 | 897 | 1.430 |
Why?
|
| Cytochrome P-450 CYP2D6 | 6 | 2016 | 108 | 1.270 |
Why?
|
| Postmenopause | 21 | 2020 | 2515 | 1.230 |
Why?
|
| Prostate-Specific Antigen | 36 | 2024 | 2464 | 1.010 |
Why?
|
| Melanoma | 8 | 2024 | 5719 | 1.000 |
Why?
|
| Ki-67 Antigen | 9 | 2019 | 629 | 0.950 |
Why?
|
| Clinical Trials as Topic | 17 | 2022 | 8041 | 0.930 |
Why?
|
| Neoplasms, Hormone-Dependent | 13 | 2018 | 409 | 0.870 |
Why?
|
| Neoplasm Recurrence, Local | 31 | 2024 | 9373 | 0.850 |
Why?
|
| Disease-Free Survival | 43 | 2024 | 6832 | 0.850 |
Why?
|
| Antineoplastic Agents | 28 | 2020 | 13648 | 0.760 |
Why?
|
| Neoplasm Staging | 34 | 2024 | 11206 | 0.680 |
Why?
|
| Androgen Antagonists | 13 | 2024 | 1411 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 28 | 2024 | 10383 | 0.620 |
Why?
|
| Prostatectomy | 13 | 2024 | 1782 | 0.610 |
Why?
|
| Aromatase | 2 | 2016 | 147 | 0.600 |
Why?
|
| Diffusion of Innovation | 1 | 2021 | 721 | 0.540 |
Why?
|
| Humans | 300 | 2025 | 765968 | 0.540 |
Why?
|
| Female | 182 | 2025 | 396112 | 0.530 |
Why?
|
| Survival Analysis | 23 | 2024 | 10070 | 0.520 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2024 | 6499 | 0.500 |
Why?
|
| Prognosis | 51 | 2025 | 29922 | 0.500 |
Why?
|
| DNA, Neoplasm | 5 | 2016 | 1742 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 13 | 2024 | 2895 | 0.480 |
Why?
|
| Middle Aged | 155 | 2025 | 223009 | 0.470 |
Why?
|
| Taxoids | 8 | 2017 | 665 | 0.460 |
Why?
|
| Research Design | 6 | 2023 | 6209 | 0.450 |
Why?
|
| Aged | 130 | 2025 | 171117 | 0.420 |
Why?
|
| Estrogens | 2 | 2020 | 1529 | 0.420 |
Why?
|
| Clinical Trials, Phase III as Topic | 9 | 2022 | 878 | 0.400 |
Why?
|
| Health Priorities | 1 | 2015 | 382 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2020 | 16047 | 0.400 |
Why?
|
| Quality of Life | 21 | 2024 | 13462 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5696 | 0.390 |
Why?
|
| Castration | 4 | 2011 | 149 | 0.390 |
Why?
|
| Mastectomy | 10 | 2021 | 1847 | 0.370 |
Why?
|
| Treatment Outcome | 60 | 2024 | 65188 | 0.370 |
Why?
|
| Leucine | 11 | 2012 | 546 | 0.370 |
Why?
|
| Antigens, Neoplasm | 8 | 2017 | 2002 | 0.370 |
Why?
|
| Cyclophosphamide | 16 | 2023 | 2228 | 0.370 |
Why?
|
| Paclitaxel | 5 | 2024 | 1728 | 0.370 |
Why?
|
| Receptors, Steroid | 1 | 2011 | 155 | 0.360 |
Why?
|
| Risk Assessment | 16 | 2021 | 24282 | 0.350 |
Why?
|
| Adult | 122 | 2025 | 223044 | 0.340 |
Why?
|
| Receptors, Androgen | 5 | 2020 | 1088 | 0.340 |
Why?
|
| Interleukin-2 | 8 | 2014 | 1896 | 0.330 |
Why?
|
| Double-Blind Method | 19 | 2022 | 12437 | 0.320 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 578 | 0.320 |
Why?
|
| Medical Oncology | 4 | 2021 | 2339 | 0.320 |
Why?
|
| Endpoint Determination | 4 | 2020 | 591 | 0.300 |
Why?
|
| Goserelin | 9 | 2012 | 126 | 0.280 |
Why?
|
| Immunohistochemistry | 16 | 2020 | 11022 | 0.280 |
Why?
|
| Proportional Hazards Models | 15 | 2021 | 12509 | 0.280 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5849 | 0.280 |
Why?
|
| Carboplatin | 2 | 2009 | 789 | 0.270 |
Why?
|
| Research | 1 | 2015 | 1975 | 0.270 |
Why?
|
| Nutritional Requirements | 16 | 2012 | 276 | 0.270 |
Why?
|
| Neoplasm Metastasis | 14 | 2021 | 4893 | 0.260 |
Why?
|
| Immunotherapy | 7 | 2022 | 4752 | 0.260 |
Why?
|
| Follow-Up Studies | 25 | 2022 | 39193 | 0.260 |
Why?
|
| Drug Administration Schedule | 12 | 2019 | 4850 | 0.250 |
Why?
|
| Cryptosporidium parvum | 1 | 2005 | 35 | 0.250 |
Why?
|
| Cryptosporidiosis | 1 | 2005 | 52 | 0.240 |
Why?
|
| Male | 139 | 2024 | 363698 | 0.240 |
Why?
|
| Adenocarcinoma | 10 | 2011 | 6364 | 0.240 |
Why?
|
| Predictive Value of Tests | 22 | 2024 | 15398 | 0.240 |
Why?
|
| Methotrexate | 12 | 2016 | 1722 | 0.230 |
Why?
|
| Lymphatic Metastasis | 9 | 2021 | 2887 | 0.230 |
Why?
|
| Ketoconazole | 3 | 2009 | 93 | 0.230 |
Why?
|
| Carbonic Anhydrases | 4 | 2010 | 107 | 0.230 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2024 | 82 | 0.230 |
Why?
|
| Penile Erection | 2 | 2017 | 100 | 0.230 |
Why?
|
| Erectile Dysfunction | 4 | 2018 | 437 | 0.230 |
Why?
|
| Androgens | 7 | 2011 | 1279 | 0.230 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2017 | 1608 | 0.220 |
Why?
|
| Prostate | 6 | 2015 | 1755 | 0.220 |
Why?
|
| Brachytherapy | 5 | 2018 | 1222 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2010 | 451 | 0.220 |
Why?
|
| Biological Assay | 1 | 2006 | 627 | 0.220 |
Why?
|
| Lysine | 5 | 2012 | 991 | 0.220 |
Why?
|
| Loss of Heterozygosity | 2 | 2016 | 663 | 0.220 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 363 | 0.210 |
Why?
|
| Pyridines | 7 | 2024 | 2888 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2018 | 1776 | 0.210 |
Why?
|
| Health Policy | 1 | 2015 | 2698 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2022 | 10729 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2024 | 561 | 0.210 |
Why?
|
| Time Factors | 28 | 2024 | 40065 | 0.210 |
Why?
|
| Survival Rate | 16 | 2020 | 12795 | 0.200 |
Why?
|
| Tumor Burden | 4 | 2018 | 1885 | 0.200 |
Why?
|
| Benzenesulfonates | 5 | 2010 | 170 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 7 | 2018 | 9249 | 0.200 |
Why?
|
| Gonadotropin-Releasing Hormone | 6 | 2018 | 1133 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2024 | 2033 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2022 | 904 | 0.190 |
Why?
|
| Kallikreins | 2 | 2020 | 220 | 0.190 |
Why?
|
| Lymph Nodes | 6 | 2019 | 3454 | 0.190 |
Why?
|
| Amino Acids | 7 | 2006 | 1709 | 0.190 |
Why?
|
| Aged, 80 and over | 41 | 2024 | 59489 | 0.190 |
Why?
|
| Thymidine Kinase | 1 | 2022 | 286 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 352 | 0.180 |
Why?
|
| Teratology | 1 | 2000 | 9 | 0.180 |
Why?
|
| Methionine | 4 | 2004 | 569 | 0.180 |
Why?
|
| Models, Economic | 3 | 2020 | 716 | 0.170 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2001 | 45 | 0.170 |
Why?
|
| Prospective Studies | 26 | 2024 | 54802 | 0.170 |
Why?
|
| Mammaplasty | 2 | 2021 | 1264 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 8611 | 0.170 |
Why?
|
| Genotype | 12 | 2018 | 13024 | 0.170 |
Why?
|
| Financing, Organized | 1 | 2021 | 201 | 0.170 |
Why?
|
| Combined Modality Therapy | 8 | 2022 | 8529 | 0.170 |
Why?
|
| Estradiol | 4 | 2018 | 1947 | 0.160 |
Why?
|
| Carcinoma | 3 | 2017 | 2312 | 0.160 |
Why?
|
| Estramustine | 3 | 2008 | 35 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2686 | 0.160 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 169 | 0.160 |
Why?
|
| Toxicology | 1 | 1999 | 102 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2021 | 224 | 0.150 |
Why?
|
| Nutrition Disorders | 3 | 2004 | 203 | 0.150 |
Why?
|
| Nomograms | 2 | 2018 | 235 | 0.150 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2011 | 134 | 0.150 |
Why?
|
| Neoplasm Proteins | 4 | 2013 | 3596 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 67 | 0.150 |
Why?
|
| Germ Cells | 2 | 2020 | 647 | 0.150 |
Why?
|
| Fluorouracil | 10 | 2012 | 1648 | 0.150 |
Why?
|
| Retrospective Studies | 33 | 2024 | 81514 | 0.150 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2004 | 452 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15652 | 0.140 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2001 | 399 | 0.140 |
Why?
|
| Treatment Refusal | 1 | 2001 | 433 | 0.140 |
Why?
|
| Breast | 4 | 2019 | 1946 | 0.140 |
Why?
|
| Research Personnel | 2 | 2021 | 590 | 0.140 |
Why?
|
| Breast Implants | 1 | 2021 | 411 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2011 | 558 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2001 | 261 | 0.140 |
Why?
|
| Orgasm | 1 | 2017 | 63 | 0.140 |
Why?
|
| Salvage Therapy | 3 | 2009 | 1272 | 0.140 |
Why?
|
| Oxidation-Reduction | 16 | 2006 | 2218 | 0.140 |
Why?
|
| Disease Progression | 14 | 2024 | 13632 | 0.140 |
Why?
|
| Decision Making | 2 | 2008 | 3965 | 0.130 |
Why?
|
| Mastectomy, Segmental | 3 | 2017 | 964 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 1083 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 561 | 0.130 |
Why?
|
| Orchiectomy | 4 | 2011 | 460 | 0.130 |
Why?
|
| Regression Analysis | 6 | 2015 | 6322 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7425 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 1999 | 993 | 0.130 |
Why?
|
| Piperazines | 2 | 2024 | 2549 | 0.130 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 1668 | 0.130 |
Why?
|
| Mediterranean Region | 1 | 2015 | 48 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2020 | 18071 | 0.130 |
Why?
|
| Ovariectomy | 2 | 2019 | 611 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2020 | 6255 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2015 | 6853 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 753 | 0.120 |
Why?
|
| Risk Factors | 17 | 2020 | 74840 | 0.120 |
Why?
|
| Telephone | 1 | 2019 | 627 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2019 | 796 | 0.120 |
Why?
|
| Albumins | 1 | 2018 | 577 | 0.120 |
Why?
|
| Carbon Isotopes | 10 | 2004 | 451 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2018 | 561 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 2428 | 0.120 |
Why?
|
| Estrone | 1 | 2016 | 234 | 0.120 |
Why?
|
| Neoplasms | 6 | 2022 | 22340 | 0.120 |
Why?
|
| Ear Neoplasms | 1 | 2015 | 118 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2010 | 3513 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 171 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 4 | 2022 | 995 | 0.120 |
Why?
|
| Age Factors | 10 | 2019 | 18380 | 0.120 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 310 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2023 | 8067 | 0.110 |
Why?
|
| DNA | 2 | 2020 | 7202 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2024 | 3047 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2010 | 995 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 2631 | 0.110 |
Why?
|
| Treatment Failure | 4 | 2016 | 2652 | 0.110 |
Why?
|
| Phenylalanine | 2 | 2006 | 367 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 916 | 0.110 |
Why?
|
| Epirubicin | 1 | 2013 | 82 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 3602 | 0.110 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 9525 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 731 | 0.110 |
Why?
|
| Multivariate Analysis | 10 | 2021 | 12056 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2013 | 94 | 0.110 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 826 | 0.110 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1884 | 0.100 |
Why?
|
| Rectum | 2 | 2016 | 896 | 0.100 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2013 | 122 | 0.100 |
Why?
|
| Amino Acids, Sulfur | 2 | 2004 | 16 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4562 | 0.100 |
Why?
|
| Alkaline Phosphatase | 2 | 2007 | 854 | 0.100 |
Why?
|
| India | 12 | 2006 | 2334 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 920 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1259 | 0.100 |
Why?
|
| Cystine | 2 | 2004 | 96 | 0.100 |
Why?
|
| Sjogren's Syndrome | 1 | 2014 | 239 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 146 | 0.100 |
Why?
|
| Viscera | 2 | 2003 | 137 | 0.100 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2011 | 16 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2009 | 2056 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2013 | 122 | 0.100 |
Why?
|
| Mutation | 10 | 2020 | 30198 | 0.100 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 114 | 0.090 |
Why?
|
| Diet | 11 | 2012 | 8086 | 0.090 |
Why?
|
| Dietary Proteins | 3 | 2003 | 959 | 0.090 |
Why?
|
| Testosterone | 5 | 2011 | 2494 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2018 | 569 | 0.090 |
Why?
|
| Threonine | 2 | 2002 | 272 | 0.090 |
Why?
|
| Fertilization in Vitro | 3 | 2005 | 1306 | 0.090 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 28 | 0.090 |
Why?
|
| South America | 1 | 2011 | 179 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 790 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 471 | 0.090 |
Why?
|
| Pyrroles | 4 | 2010 | 1119 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| Urologic Diseases | 1 | 2013 | 245 | 0.090 |
Why?
|
| New Zealand | 1 | 2011 | 359 | 0.090 |
Why?
|
| Incidence | 6 | 2022 | 21480 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2015 | 2352 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 360 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 430 | 0.090 |
Why?
|
| Cystic Fibrosis | 5 | 2004 | 1287 | 0.090 |
Why?
|
| Organic Anion Transporters | 1 | 2011 | 101 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 62 | 0.090 |
Why?
|
| Interferon-alpha | 2 | 2005 | 910 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1106 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 150 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 2011 | 593 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 323 | 0.080 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 28 | 0.080 |
Why?
|
| Biomedical Research | 2 | 2021 | 3458 | 0.080 |
Why?
|
| Niacinamide | 5 | 2010 | 419 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 274 | 0.080 |
Why?
|
| Branched DNA Signal Amplification Assay | 1 | 2009 | 4 | 0.080 |
Why?
|
| Hotlines | 1 | 2010 | 55 | 0.080 |
Why?
|
| Norovirus | 1 | 2010 | 36 | 0.080 |
Why?
|
| Amenorrhea | 1 | 2013 | 470 | 0.080 |
Why?
|
| Selenium | 2 | 2011 | 419 | 0.080 |
Why?
|
| Azasteroids | 1 | 2009 | 37 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 970 | 0.080 |
Why?
|
| Database Management Systems | 1 | 2011 | 263 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2021 | 2039 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 4247 | 0.080 |
Why?
|
| Disease Notification | 1 | 2010 | 95 | 0.080 |
Why?
|
| Hot Flashes | 3 | 2017 | 330 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2822 | 0.080 |
Why?
|
| Nitrogen | 2 | 2001 | 346 | 0.080 |
Why?
|
| Teratogens | 2 | 2000 | 121 | 0.080 |
Why?
|
| Oncogene Fusion | 1 | 2009 | 84 | 0.080 |
Why?
|
| World Health Organization | 1 | 2015 | 1328 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2013 | 320 | 0.080 |
Why?
|
| Cross-Over Studies | 3 | 2011 | 2108 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3925 | 0.080 |
Why?
|
| Biopsy | 8 | 2021 | 6763 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 679 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2021 | 3956 | 0.080 |
Why?
|
| Cohort Studies | 17 | 2019 | 41649 | 0.080 |
Why?
|
| Indoles | 4 | 2010 | 1839 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Ventricular Function, Right | 2 | 2004 | 629 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1127 | 0.080 |
Why?
|
| Phenylurea Compounds | 5 | 2010 | 536 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2013 | 506 | 0.080 |
Why?
|
| Internet | 2 | 2019 | 3106 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 7 | 2020 | 5526 | 0.080 |
Why?
|
| Biopsy, Needle | 4 | 2010 | 1628 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 6069 | 0.070 |
Why?
|
| Alleles | 3 | 2015 | 6897 | 0.070 |
Why?
|
| Menopause | 3 | 2011 | 1659 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2007 | 303 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2010 | 229 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 5337 | 0.070 |
Why?
|
| Hepatitis A Vaccines | 1 | 2007 | 26 | 0.070 |
Why?
|
| Genes, myc | 1 | 2009 | 393 | 0.070 |
Why?
|
| ras Proteins | 1 | 2013 | 1053 | 0.070 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 1153 | 0.070 |
Why?
|
| North America | 1 | 2011 | 1285 | 0.070 |
Why?
|
| Australia | 1 | 2011 | 1258 | 0.070 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2008 | 84 | 0.070 |
Why?
|
| Consensus | 1 | 2018 | 3202 | 0.070 |
Why?
|
| Cholesterol | 1 | 2017 | 2898 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2016 | 10429 | 0.070 |
Why?
|
| Spin Labels | 1 | 2009 | 334 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2012 | 637 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2012 | 1216 | 0.070 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 2531 | 0.070 |
Why?
|
| Uncertainty | 1 | 2012 | 761 | 0.070 |
Why?
|
| RNA | 1 | 2017 | 2717 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1731 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 705 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2020 | 3714 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1188 | 0.070 |
Why?
|
| Hepatitis A | 1 | 2007 | 126 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 452 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 616 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2008 | 284 | 0.070 |
Why?
|
| Self Report | 2 | 2016 | 3770 | 0.070 |
Why?
|
| Valine | 2 | 2006 | 410 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2000 | 335 | 0.070 |
Why?
|
| Anthropometry | 6 | 2012 | 1338 | 0.070 |
Why?
|
| Vomiting | 1 | 2010 | 647 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2010 | 493 | 0.070 |
Why?
|
| Models, Biological | 4 | 2013 | 9443 | 0.070 |
Why?
|
| Quadriplegia | 1 | 2008 | 227 | 0.070 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2017 | 59 | 0.070 |
Why?
|
| Pregnancy Rate | 2 | 2009 | 655 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2013 | 2230 | 0.060 |
Why?
|
| Linear Models | 8 | 2009 | 5876 | 0.060 |
Why?
|
| South Africa | 1 | 2011 | 1867 | 0.060 |
Why?
|
| Colorectal Neoplasms | 3 | 2013 | 6942 | 0.060 |
Why?
|
| Arsenicals | 1 | 2006 | 117 | 0.060 |
Why?
|
| Influenza, Human | 2 | 2011 | 1539 | 0.060 |
Why?
|
| Imidazolidines | 1 | 2005 | 38 | 0.060 |
Why?
|
| Wales | 1 | 2005 | 87 | 0.060 |
Why?
|
| Antineoplastic Protocols | 2 | 2020 | 47 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 1044 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2009 | 1827 | 0.060 |
Why?
|
| Infusions, Intravenous | 6 | 2013 | 2229 | 0.060 |
Why?
|
| Vinblastine | 1 | 2007 | 483 | 0.060 |
Why?
|
| Models, Theoretical | 3 | 2019 | 3564 | 0.060 |
Why?
|
| Chloride Channels | 2 | 2004 | 221 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2005 | 43 | 0.060 |
Why?
|
| International Cooperation | 1 | 2012 | 1432 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 2 | 2003 | 943 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1761 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 376 | 0.060 |
Why?
|
| Proline | 1 | 2006 | 453 | 0.060 |
Why?
|
| Europe | 1 | 2011 | 3423 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 501 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 301 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2016 | 244 | 0.060 |
Why?
|
| Coronary Artery Bypass | 3 | 2004 | 2186 | 0.060 |
Why?
|
| Zoonoses | 1 | 2005 | 181 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 402 | 0.060 |
Why?
|
| United States | 10 | 2021 | 72903 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2010 | 2631 | 0.060 |
Why?
|
| Young Adult | 9 | 2020 | 59889 | 0.060 |
Why?
|
| Early Detection of Cancer | 3 | 2015 | 3236 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 1600 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 708 | 0.060 |
Why?
|
| Water Supply | 1 | 2005 | 204 | 0.060 |
Why?
|
| England | 1 | 2005 | 533 | 0.060 |
Why?
|
| School Health Services | 1 | 2007 | 387 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2009 | 1024 | 0.060 |
Why?
|
| Formaldehyde | 2 | 2016 | 352 | 0.060 |
Why?
|
| Lidocaine | 2 | 2000 | 550 | 0.060 |
Why?
|
| Acid Phosphatase | 1 | 2003 | 139 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 976 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2008 | 800 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1050 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2012 | 2020 | 0.050 |
Why?
|
| Community Health Services | 1 | 2008 | 657 | 0.050 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2003 | 64 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2003 | 55 | 0.050 |
Why?
|
| Sirolimus | 2 | 2007 | 1545 | 0.050 |
Why?
|
| Finasteride | 1 | 2004 | 86 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 20124 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2007 | 2788 | 0.050 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2006 | 266 | 0.050 |
Why?
|
| Disease Outbreaks | 2 | 2010 | 1759 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2007 | 1611 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2013 | 58 | 0.050 |
Why?
|
| Remission Induction | 2 | 2006 | 2411 | 0.050 |
Why?
|
| Health Care Costs | 3 | 2018 | 3242 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2005 | 2263 | 0.050 |
Why?
|
| Antioxidants | 1 | 2011 | 1670 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2009 | 2850 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2016 | 6610 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 618 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 68 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1119 | 0.050 |
Why?
|
| Vaccination | 2 | 2007 | 3426 | 0.050 |
Why?
|
| Infertility | 1 | 2009 | 654 | 0.050 |
Why?
|
| Ovarian Follicle | 1 | 2004 | 243 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 430 | 0.050 |
Why?
|
| Maternal Age | 1 | 2005 | 804 | 0.050 |
Why?
|
| Body Weight | 4 | 2017 | 4622 | 0.050 |
Why?
|
| Stem Cells | 1 | 2015 | 3540 | 0.050 |
Why?
|
| Calorimetry, Indirect | 4 | 2003 | 176 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2002 | 125 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2942 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3475 | 0.050 |
Why?
|
| Live Birth | 1 | 2005 | 516 | 0.050 |
Why?
|
| Odds Ratio | 4 | 2018 | 9649 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 14751 | 0.050 |
Why?
|
| Fatigue | 3 | 2017 | 1549 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 728 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2004 | 700 | 0.050 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2003 | 177 | 0.050 |
Why?
|
| Anilides | 1 | 2004 | 415 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3318 | 0.050 |
Why?
|
| Dietary Carbohydrates | 2 | 2003 | 894 | 0.050 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2910 | 0.050 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 682 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 1229 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 538 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4520 | 0.040 |
Why?
|
| Adolescent | 13 | 2020 | 88835 | 0.040 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2000 | 29 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 416 | 0.040 |
Why?
|
| Tryptophan | 1 | 2003 | 483 | 0.040 |
Why?
|
| Bronchial Spasm | 1 | 2000 | 71 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2011 | 2590 | 0.040 |
Why?
|
| Gene Expression | 1 | 2013 | 7584 | 0.040 |
Why?
|
| Systole | 1 | 2002 | 935 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1140 | 0.040 |
Why?
|
| Uridine | 1 | 2000 | 135 | 0.040 |
Why?
|
| Breath Tests | 4 | 2003 | 297 | 0.040 |
Why?
|
| Chlorides | 1 | 2003 | 666 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 491 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2000 | 66 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2172 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2002 | 1090 | 0.040 |
Why?
|
| Ammonium Chloride | 1 | 1999 | 72 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1166 | 0.040 |
Why?
|
| Caseins | 1 | 2000 | 105 | 0.040 |
Why?
|
| American Medical Association | 1 | 2020 | 60 | 0.040 |
Why?
|
| Age Distribution | 1 | 2005 | 2858 | 0.040 |
Why?
|
| Mitoxantrone | 3 | 2007 | 148 | 0.040 |
Why?
|
| Nipples | 1 | 2021 | 222 | 0.040 |
Why?
|
| Albuterol | 1 | 2000 | 211 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 2660 | 0.040 |
Why?
|
| Seasons | 1 | 2005 | 1524 | 0.040 |
Why?
|
| Nootropic Agents | 1 | 2000 | 159 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 240 | 0.040 |
Why?
|
| Cell Line, Tumor | 6 | 2013 | 17075 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2010 | 6203 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2018 | 13039 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 6309 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2012 | 3425 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1432 | 0.040 |
Why?
|
| Anticipation, Genetic | 1 | 1998 | 5 | 0.040 |
Why?
|
| Animals | 13 | 2022 | 168764 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 784 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 206 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 2054 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2003 | 2002 | 0.040 |
Why?
|
| Choline | 1 | 2000 | 510 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 150 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 633 | 0.040 |
Why?
|
| Pregnancy | 6 | 2020 | 30260 | 0.040 |
Why?
|
| Tyrosine | 1 | 2003 | 1428 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1999 | 353 | 0.040 |
Why?
|
| Reference Values | 5 | 2004 | 4908 | 0.040 |
Why?
|
| Cysteine | 2 | 2000 | 898 | 0.040 |
Why?
|
| Comorbidity | 2 | 2013 | 10563 | 0.040 |
Why?
|
| Tachycardia | 1 | 2000 | 594 | 0.040 |
Why?
|
| Fasting | 5 | 2003 | 1606 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2012 | 3985 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 1378 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2004 | 763 | 0.040 |
Why?
|
| Registries | 1 | 2014 | 8297 | 0.040 |
Why?
|
| Risk | 4 | 2018 | 9591 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 297 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2003 | 1620 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2008 | 3595 | 0.040 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 262 | 0.040 |
Why?
|
| Pancreas | 1 | 2004 | 1700 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2004 | 1087 | 0.040 |
Why?
|
| Urea | 1 | 1999 | 448 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2002 | 1093 | 0.040 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2001 | 543 | 0.030 |
Why?
|
| Ileum | 1 | 1999 | 558 | 0.030 |
Why?
|
| General Surgery | 1 | 2008 | 1722 | 0.030 |
Why?
|
| Malnutrition | 1 | 2003 | 629 | 0.030 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 2004 | 845 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2004 | 916 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2009 | 3618 | 0.030 |
Why?
|
| Logistic Models | 5 | 2011 | 13266 | 0.030 |
Why?
|
| Magnesium | 1 | 2000 | 813 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4958 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 514 | 0.030 |
Why?
|
| Survivors | 1 | 2007 | 2372 | 0.030 |
Why?
|
| Genomics | 2 | 2025 | 5929 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2004 | 3675 | 0.030 |
Why?
|
| Glycine | 1 | 2000 | 672 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3819 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2001 | 728 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4108 | 0.030 |
Why?
|
| Polymethacrylic Acids | 1 | 1996 | 31 | 0.030 |
Why?
|
| Chewing Gum | 1 | 1996 | 40 | 0.030 |
Why?
|
| Nasal Mucosa | 3 | 2004 | 416 | 0.030 |
Why?
|
| Carbon Dioxide | 4 | 2001 | 1137 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9601 | 0.030 |
Why?
|
| Observer Variation | 2 | 2019 | 2615 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 745 | 0.030 |
Why?
|
| Fixatives | 1 | 2016 | 90 | 0.030 |
Why?
|
| Biometry | 1 | 1999 | 571 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6493 | 0.030 |
Why?
|
| Melatonin | 1 | 2001 | 674 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2020 | 377 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2013 | 12131 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15747 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2001 | 970 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2020 | 621 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2009 | 2821 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2001 | 1673 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1701 | 0.030 |
Why?
|
| Sweating | 1 | 2016 | 155 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2004 | 1364 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3273 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2011 | 42500 | 0.030 |
Why?
|
| Polyvinyls | 1 | 1996 | 153 | 0.030 |
Why?
|
| Checklist | 1 | 2022 | 848 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2567 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 2001 | 898 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1341 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2001 | 1262 | 0.030 |
Why?
|
| Urinalysis | 1 | 2017 | 368 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2017 | 284 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 1996 | 119 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 1996 | 144 | 0.030 |
Why?
|
| Monocytes | 1 | 2004 | 2595 | 0.030 |
Why?
|
| Case-Control Studies | 5 | 2018 | 22223 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2008 | 3461 | 0.030 |
Why?
|
| Benzamides | 1 | 2020 | 1377 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2022 | 981 | 0.030 |
Why?
|
| Thiazoles | 1 | 2022 | 1529 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 786 | 0.030 |
Why?
|
| Mice | 8 | 2015 | 81819 | 0.030 |
Why?
|
| Medical History Taking | 2 | 2004 | 777 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 1995 | 228 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 791 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1602 | 0.030 |
Why?
|
| Infant | 5 | 2011 | 36386 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2001 | 778 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2018 | 5089 | 0.030 |
Why?
|
| Patient Selection | 1 | 2006 | 4255 | 0.030 |
Why?
|
| Clonidine | 1 | 1995 | 165 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1774 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2004 | 1968 | 0.030 |
Why?
|
| Pericarditis, Constrictive | 1 | 1994 | 46 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 4058 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2024 | 3222 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9071 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 2000 | 1015 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2013 | 163 | 0.030 |
Why?
|
| Refugees | 1 | 2002 | 614 | 0.030 |
Why?
|
| Oxazoles | 1 | 1995 | 198 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2004 | 1566 | 0.030 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 1377 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 762 | 0.030 |
Why?
|
| Saccades | 1 | 1995 | 230 | 0.030 |
Why?
|
| Hormones | 1 | 2017 | 863 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2018 | 1192 | 0.030 |
Why?
|
| Heterozygote | 3 | 2004 | 2794 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1587 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2001 | 2864 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1737 | 0.030 |
Why?
|
| Health Surveys | 1 | 2003 | 4056 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2001 | 2203 | 0.030 |
Why?
|
| Respiratory Tract Infections | 2 | 2004 | 1008 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2000 | 1303 | 0.030 |
Why?
|
| Obesity | 2 | 2012 | 13076 | 0.030 |
Why?
|
| Enoxaparin | 1 | 1995 | 390 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1999 | 2721 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2009 | 2505 | 0.020 |
Why?
|
| Viral Load | 1 | 2001 | 3386 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1187 | 0.020 |
Why?
|
| Food | 3 | 2003 | 764 | 0.020 |
Why?
|
| Communication | 1 | 2006 | 3916 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3850 | 0.020 |
Why?
|
| Fetus | 1 | 1999 | 1870 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1009 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2001 | 1090 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2002 | 2136 | 0.020 |
Why?
|
| Deuterium | 2 | 2003 | 104 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2015 | 4015 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2011 | 42 | 0.020 |
Why?
|
| Ifosfamide | 2 | 2003 | 233 | 0.020 |
Why?
|
| Synovitis | 1 | 1993 | 209 | 0.020 |
Why?
|
| Retreatment | 1 | 2013 | 598 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2004 | 2023 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 452 | 0.020 |
Why?
|
| Forecasting | 2 | 2011 | 2936 | 0.020 |
Why?
|
| Blood Cells | 1 | 2013 | 307 | 0.020 |
Why?
|
| Child | 7 | 2011 | 80564 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 199 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2010 | 26346 | 0.020 |
Why?
|
| Dairying | 1 | 1991 | 12 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 272 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2013 | 297 | 0.020 |
Why?
|
| Mitral Valve | 1 | 1999 | 1476 | 0.020 |
Why?
|
| Nicotine | 1 | 1996 | 682 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2014 | 290 | 0.020 |
Why?
|
| Pandemics | 1 | 2011 | 8703 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 545 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2927 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3432 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 373 | 0.020 |
Why?
|
| Physicians | 1 | 2008 | 4588 | 0.020 |
Why?
|
| Epithelium | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2017 | 1494 | 0.020 |
Why?
|
| Probability | 2 | 2009 | 2475 | 0.020 |
Why?
|
| Etoposide | 2 | 2003 | 636 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 1998 | 1051 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 1991 | 126 | 0.020 |
Why?
|
| Paper | 1 | 2010 | 80 | 0.020 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 15880 | 0.020 |
Why?
|
| Axilla | 1 | 2013 | 615 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2011 | 238 | 0.020 |
Why?
|
| Recurrence | 2 | 2018 | 8501 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2008 | 18293 | 0.020 |
Why?
|
| Chronic Disease | 5 | 2004 | 9347 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1999 | 1414 | 0.020 |
Why?
|
| Health Services | 1 | 1995 | 756 | 0.020 |
Why?
|
| General Practice | 1 | 2011 | 102 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1149 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 399 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 8731 | 0.020 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2009 | 99 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2011 | 256 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2865 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7421 | 0.020 |
Why?
|
| Clomiphene | 1 | 2009 | 71 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3807 | 0.020 |
Why?
|
| Kinetics | 3 | 2002 | 6274 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 774 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 2844 | 0.020 |
Why?
|
| Liposomes | 1 | 2013 | 788 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 895 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2003 | 691 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 137 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 1500 | 0.020 |
Why?
|
| Fertility Agents, Female | 1 | 2009 | 101 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2009 | 152 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 166 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2009 | 101 | 0.020 |
Why?
|
| Body Composition | 2 | 2012 | 2439 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2013 | 722 | 0.020 |
Why?
|
| SOXC Transcription Factors | 1 | 2008 | 42 | 0.020 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2009 | 196 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 714 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 9550 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2009 | 240 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3655 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2007 | 2056 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 36532 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2008 | 180 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Endocrine System | 1 | 2008 | 111 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 293 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 1939 | 0.020 |
Why?
|
| Longevity | 1 | 2015 | 1087 | 0.020 |
Why?
|
| beta Catenin | 1 | 2013 | 1043 | 0.020 |
Why?
|
| Hand | 1 | 1993 | 909 | 0.020 |
Why?
|
| Hypotension | 1 | 2013 | 885 | 0.020 |
Why?
|
| Phenotype | 3 | 2016 | 16721 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2009 | 277 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2006 | 8733 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 2120 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 798 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2016 | 1328 | 0.020 |
Why?
|
| Genetic Services | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2006 | 139 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 814 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 2081 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2016 | 1950 | 0.020 |
Why?
|
| Warfarin | 1 | 1995 | 1494 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 1881 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1999 | 3837 | 0.020 |
Why?
|
| Rehabilitation Centers | 1 | 2008 | 246 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15842 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8875 | 0.020 |
Why?
|
| Isoleucine | 1 | 2006 | 109 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 236 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1941 | 0.020 |
Why?
|
| Asthma | 2 | 2004 | 6270 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 1965 | 0.020 |
Why?
|
| Population Groups | 1 | 2006 | 209 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 2728 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1326 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 2033 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 822 | 0.010 |
Why?
|
| Feces | 2 | 2003 | 1504 | 0.010 |
Why?
|
| Physical Examination | 1 | 1991 | 1266 | 0.010 |
Why?
|
| DNA Primers | 1 | 2009 | 2825 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 639 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2867 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 433 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2008 | 634 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2014 | 1582 | 0.010 |
Why?
|
| Necrosis | 1 | 2009 | 1617 | 0.010 |
Why?
|
| Faculty | 1 | 2007 | 384 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 1991 | 622 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 612 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2004 | 398 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1181 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 10850 | 0.010 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 115 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3089 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 5370 | 0.010 |
Why?
|
| Social Adjustment | 1 | 2006 | 633 | 0.010 |
Why?
|
| Milrinone | 1 | 2004 | 87 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 2003 | 57 | 0.010 |
Why?
|
| Placebos | 2 | 2000 | 1659 | 0.010 |
Why?
|
| Epidermis | 1 | 2006 | 538 | 0.010 |
Why?
|
| Lens Plant | 1 | 2003 | 5 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 2014 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1441 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 175 | 0.010 |
Why?
|
| Exercise | 1 | 2000 | 5937 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Ion Transport | 1 | 2004 | 322 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 1744 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 1151 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 682 | 0.010 |
Why?
|
| Sweat | 1 | 2003 | 57 | 0.010 |
Why?
|
| Interferons | 1 | 2007 | 714 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 5753 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1478 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1991 | 1456 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2009 | 1365 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 2003 | 122 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 2002 | 164 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2007 | 1417 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2003 | 107 | 0.010 |
Why?
|
| Infant Formula | 1 | 2004 | 192 | 0.010 |
Why?
|
| Yugoslavia | 1 | 2002 | 23 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2004 | 327 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2004 | 358 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 2003 | 261 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2009 | 3624 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 2003 | 0.010 |
Why?
|
| Radioactive Tracers | 1 | 2002 | 61 | 0.010 |
Why?
|
| Cell Division | 1 | 2009 | 4475 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 1525 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2070 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 457 | 0.010 |
Why?
|
| Neutropenia | 1 | 2007 | 893 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 1119 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1641 | 0.010 |
Why?
|
| Divorce | 1 | 2001 | 78 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2424 | 0.010 |
Why?
|
| Filgrastim | 1 | 2001 | 131 | 0.010 |
Why?
|
| Organ Size | 1 | 2006 | 2260 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 655 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 1083 | 0.010 |
Why?
|
| Cytidine Triphosphate | 1 | 2000 | 17 | 0.010 |
Why?
|
| Thrombosis | 1 | 1995 | 2949 | 0.010 |
Why?
|
| Uridine Triphosphate | 1 | 2000 | 29 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 4618 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2001 | 150 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 583 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 586 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2006 | 1113 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1820 | 0.010 |
Why?
|
| Cytidine | 1 | 2000 | 59 | 0.010 |
Why?
|
| Keto Acids | 1 | 2000 | 32 | 0.010 |
Why?
|
| Epinephrine | 1 | 2004 | 783 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2000 | 317 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 3067 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2001 | 227 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6823 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3797 | 0.010 |
Why?
|
| Rabbits | 1 | 2006 | 4734 | 0.010 |
Why?
|
| Anesthesia, Inhalation | 1 | 2000 | 216 | 0.010 |
Why?
|
| Diet, Protein-Restricted | 1 | 2000 | 73 | 0.010 |
Why?
|
| Mesentery | 1 | 2000 | 199 | 0.010 |
Why?
|
| Tritium | 1 | 2000 | 702 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4137 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2006 | 1247 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 1526 | 0.010 |
Why?
|
| Vaccines | 1 | 2007 | 841 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1995 | 6273 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2001 | 656 | 0.010 |
Why?
|
| Sodium | 1 | 2004 | 1591 | 0.010 |
Why?
|
| Ileostomy | 1 | 1999 | 122 | 0.010 |
Why?
|
| Minority Groups | 1 | 2006 | 1207 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 2429 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2584 | 0.010 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 405 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2004 | 1828 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 515 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 26318 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2453 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2000 | 543 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2010 | 3681 | 0.010 |
Why?
|
| Affect | 1 | 2006 | 1500 | 0.010 |
Why?
|
| Nutrition Policy | 1 | 2002 | 467 | 0.010 |
Why?
|
| Cognition | 1 | 2016 | 7049 | 0.010 |
Why?
|
| Heart Rate | 2 | 2004 | 4204 | 0.010 |
Why?
|
| Body Temperature | 1 | 2001 | 779 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2243 | 0.010 |
Why?
|
| Sample Size | 1 | 2001 | 845 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 6919 | 0.010 |
Why?
|
| Glucagon | 1 | 2000 | 533 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2004 | 1187 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2207 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2001 | 1589 | 0.010 |
Why?
|
| Sex Factors | 2 | 2001 | 10603 | 0.010 |
Why?
|
| Students | 1 | 2007 | 1734 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1993 | 3733 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6220 | 0.010 |
Why?
|
| Fertilization | 1 | 1998 | 197 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 1154 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 1490 | 0.010 |
Why?
|
| Rats | 2 | 2006 | 23707 | 0.010 |
Why?
|
| Isoflurane | 1 | 2000 | 384 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2008 | 2517 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2009 | 2041 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2003 | 1470 | 0.010 |
Why?
|
| Depression | 1 | 2017 | 8237 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 4448 | 0.010 |
Why?
|
| Death | 1 | 2001 | 686 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 9296 | 0.010 |
Why?
|
| Counseling | 1 | 2004 | 1551 | 0.010 |
Why?
|
| Hospitals | 1 | 2010 | 3888 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 2192 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 8278 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1792 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2004 | 1806 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2002 | 1138 | 0.010 |
Why?
|
| Action Potentials | 1 | 2003 | 1838 | 0.010 |
Why?
|
| Insulin | 2 | 2000 | 6599 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 1936 | 0.010 |
Why?
|
| Expectorants | 1 | 1995 | 22 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 573 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 7599 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2817 | 0.010 |
Why?
|
| Sarcoma | 1 | 2006 | 1802 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2001 | 2341 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 2267 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 2141 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2000 | 1237 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2334 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 1515 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 1915 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2004 | 8532 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2002 | 1406 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8626 | 0.010 |
Why?
|
| Pericardiectomy | 1 | 1994 | 46 | 0.010 |
Why?
|
| Brain | 1 | 2001 | 27171 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7232 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3690 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7838 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2004 | 4184 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 3785 | 0.010 |
Why?
|
| Decision Trees | 1 | 1995 | 509 | 0.010 |
Why?
|
| Markov Chains | 1 | 1996 | 968 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8923 | 0.010 |
Why?
|
| Tourniquets | 1 | 1993 | 111 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 7478 | 0.010 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1995 | 530 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3278 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 5045 | 0.010 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 1991 | 11 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2004 | 3928 | 0.010 |
Why?
|
| Poverty | 1 | 2003 | 2714 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 7562 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 5993 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 14652 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 22332 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 4671 | 0.010 |
Why?
|
| Rural Health | 1 | 1991 | 301 | 0.000 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 1991 | 144 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2892 | 0.000 |
Why?
|
| Health Status | 1 | 2002 | 4080 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 11888 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 2592 | 0.000 |
Why?
|
| New York | 1 | 1991 | 880 | 0.000 |
Why?
|
| Drug Prescriptions | 1 | 1996 | 1662 | 0.000 |
Why?
|
| Kidney | 1 | 2000 | 7066 | 0.000 |
Why?
|
| Parents | 1 | 1998 | 3592 | 0.000 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 6544 | 0.000 |
Why?
|
| Smoking Cessation | 1 | 1996 | 2084 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1995 | 2598 | 0.000 |
Why?
|
| Smoking | 1 | 1996 | 9081 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1991 | 4544 | 0.000 |
Why?
|
| Hospitalization | 1 | 1995 | 10808 | 0.000 |
Why?
|